Publication | Closed Access

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer

Metastatic Breast CancerOncology6-Week IntervalBreast OncologyMedicineEortc 10968Breast CancerAnti-cancer AgentCancer TreatmentPharmacologyRadiation Oncology